Mammary Cell News 9.33 August 24, 2017 | |
| |
TOP STORYSIRT7 Antagonizes TGF-β Signaling and Inhibits Breast Cancer Metastasis Scientists showed that protein deacetylase SIRT7 is significantly downregulated in breast cancer lung metastases in humans and mice, and predicts metastasis-free survival. SIRT7 deficiency promoted breast cancer cell metastasis, while temporal expression of Sirt7 inhibited metastasis in a polyomavirus middle T antigen breast cancer model. [Nat Commun] Full Article | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)LABORATORY RESEARCHResearchers characterized and targeted drug-tolerant BRCA1-deficient tumor cells that cause residual disease and subsequent tumor relapse. They studied responses to various mono- and bifunctional alkylating agents in a genetically engineered mouse model for BRCA1/p53-mutant breast cancer. [Clin Cancer Res] Abstract Investigators report the first small-molecule inhibitor of human PI4KIIα. 2-(3-(4-Chlorobenzoyl)thioureido)-4-ethyl-5-methylthiophene-3-carboxamide (PI-273) exhibited the greatest inhibitory effect on PI4KIIα kinase activity and suppressed cell proliferation. PI-273 reduced PI4P content, cell viability, and AKT signaling in wild-type MCF-7 cells but not in PI4KIIα knockout MCF-7 cells, indicating that PI-273 is highly selective for PI4KIIα. [Cancer Res] Abstract | Full Article Scientists characterized a compound that inhibits thousand-and-one amino acid kinase (TAOK) 1 and TAOK2 activity with IC50 values of 11-15 nM, is ATP-competitive and targets these kinases selectively. TAOK inhibition or depletion in centrosome amplified SKBR3 or BT549 breast cancer cell models increased the mitotic population, the percentages of mitotic cells displaying amplified centrosomes and multipolar spindles, induced cell death and inhibited cell growth. [Mol Cancer Ther] Abstract Researchers showed that BHX suppresses MDA-MB-231 cell viability and colony formation in a dose-dependent manner, and induces apoptosis and G0/G1 phase arrest. BHX-treated breast cancer cells showed morphological characteristics of cells undergoing apoptosis. [Sci Rep] Full Article Investigators established that SOX2 silencing of cancer stem cells along with paclitaxel treatment reduced SOX2-ABCG2-TWIST1 expression, disrupted sphere forming capacity and also reduced invasiveness by retaining epithelial-like properties of the cells. [Sci Rep] Full Article Myc Mediates Cancer Stem-Like Cells and EMT Changes in Triple Negative Breast Cancers Cells Scientists studied the effects of c-Myc overexpression on cancer stem cells (CSCs) and chemotherapy in African American (AA), and European American derived triple negative breast cancer cell lines. Overexpression of c-Myc in AA derived MDA-MB-468 cells resulted in a significant increase in CSCs and with minimal changes in epithelial-to-mesenchymal transition (EMT) compared to the control group. [PLoS One] Full Article CLINICAL RESEARCHTo address conflicting results and concerns that the findings for white blood cells (WBC) DNA methylation in some prior studies may reflect disease effects, researchers evaluated the relationship between global levels of WBC DNA methylation in white blood cells and breast cancer risk in a case-control study nested within the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) cohort. [Breast Cancer Res] Full Article The authors examined whether genetic polymorphisms in the capecitabine activation pathway and CDA enzymatic activity were associated with prognosis, benefit from capecitabine-containing treatment or capecitabine-related toxicities. The study population comprised 188 metastatic breast cancer patients of the ATX trial randomized for first-line paclitaxel and bevacizumab with or without capecitabine. [Pharmacol Res] Abstract | Graphical Abstract Scientists tested the predictive potential of the BRCA1-like profile for adjuvant non-myeloablative, intensified dose-dense chemotherapy in the GAIN trial. [Breast Cancer Res Treat] Abstract | |
| |
REVIEWSMUC1 Story: Great Expectations, Disappointments and the Renaissance More than 200 papers on MUC1 were published in 2016; the majority of them are dedicated to MUC1-related anticancer diagnostics and therapeutics. Scientists review the history of MUC1 studies from the very first attempts to reveal its functions to the ongoing renaissance. [Curr Med Chem] Abstract Tumor-Derived Exosomes: Potential Biomarker or Therapeutic Target in Breast Cancer? The authors highlight the potential roles of exosomes in normal and breast cancer cells and their potential applications as biomarkers with special focus on their potential applications in treatment of breast cancer. [J Cell Biochem] Abstract Nanocarrier Based Approaches for Targeting Breast Cancer Stem Cells Nanotechnology based drug carriers (nanocarriers) offer various advantages to deliver anti-breast cancer stem cells (BCSCs) agents specifically to their target sites by overcoming their bioavailability issues. Researchers describe various strategies for targeting BCSCs using nanocarriers. [Artif Cells Nanomed Biotechnol] Abstract | Graphical Abstract Visit our reviews page to see a complete list of reviews in the mammary cell research field. | |
| |
INDUSTRY NEWSChampions Oncology, Inc. announced a strategic collaboration with AstraZeneca to develop novel cohorts of PDX models. These models will be used in AstraZeneca’s oncology R&D programs in breast and lung cancer, in addition to being added to Champions’ existing TumorGraft bank for translational oncology research for academic and industry customers. [Champions Oncology, Inc.] Press Release CPRIT Awards $13M for Prevention, Research, Recruitment Researchers in the NCI-designated Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine have received $13,107,956 from the Cancer Prevention and Research Institute of Texas for six new grants focused on evidence-based cancer prevention services, the recruitment of an established investigator, individual investigator and early translational research and core facility support. [Baylor College of Medicine] Press Release Novartis announced that the European Commission approved Kisqali® (ribociclib) in combination with an aromatase inhibitor for treatment of postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2–) locally advanced or metastatic breast cancer as initial endocrine-based therapy. [Novartis AG] Press Release The Alliance Foundation Trials, LLC, in conjunction with Pfizer and six international cancer research groups, announced the launch of PATINA – a randomized, open-label, Phase III clinical study of the cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor palbociclib (also known as IBRANCE®). [Pfizer Inc.] Press Release Celldex Therapeutics, Inc. announced that patient enrollment has been completed in the Company’s Phase IIb METRIC study of glembatumumab vedotin in patients with metastatic triple negative breast cancers that overexpress gpNMB. Glembatumumab vedotin is an antibody-drug conjugate that targets and binds to gpNMB, a protein expressed by multiple tumor types, including breast cancer. [Celldex Therapeutics, Inc.] Press Release | |
| |
POLICY NEWSBiomedical Ph.D. Program at Major Research University Drops GRE Requirement for Admission The University of Michigan’s biomedical sciences graduate program announced that it will no longer require GRE scores for its Ph.D. admissions. Following a review of the available evidence and a public discussion involving the program’s faculty, staff, and trainees, the exam’s ability to predict student performance seems “weak at best” while it significantly disadvantages women, minorities, and students from low socioeconomic backgrounds, writes Scott Barolo, director of the Program in Biomedical Sciences, in the announcement. [Science Careers] Editorial Leaked Documents Expose Long-Standing Gender Tensions at Salk Institute Senior female faculty at the Salk Institute for Biological Studies raise more than twice as much in National Institutes of Health funding for scientists working in their labs as their male counterparts, according to a 2016 internal report on “faculty issues” requested by leaders of the San Diego, California institution. Yet Salk leaders favored male scientists by granting them greater access to internal funds and other resources, the report implies, echoing gender discrimination lawsuits filed last month against the research center. [ScienceInsider] Editorial A Bold Open-Access Push in Germany Could Change the Future of Academic Publishing Over the past two years, more than 150 German libraries, universities, and research institutes have formed a united front trying to force academic publishers into a new way of doing business. Instead of buying subscriptions to specific journals, consortium members want to pay publishers an annual lump sum that covers publication costs of all papers whose first authors are at German institutions. Those papers would be freely available around the world; meanwhile, German institutions would receive access to all the publishers’ online content. [ScienceInsider] Editorial
| |
EVENTSNEW Keystone Symposia: Tumor Metabolism Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Training Fellows – Breast Cancer Research (Institute of Cancer Research) Postdoctoral Position – Mammary Tumors (Cancer Research UK Beatson Institute) Postdoctoral Training Fellow – Breast Cancer Research (Institute of Cancer Research) Clinician Investigator – Breast Cancer Research (Mayo Clinic) Research Fellows – Cancer Research (National University of Singapore) Multiple Positions – Cancer Research (National University of Singapore) Postdoctoral Position – Breast Cancer Research (Massachusetts General Hospital Cancer Center) Higher Scientific Officer – Breast Cancer Research (Institute of Cancer Research) PhD Student – Breast Cancer Biology (VIB-KULeuven Center for Cancer Biology) Associate Medical Director/Medical Director – Breast Cancer (Genentech, Inc.) Postdoctoral Fellow – Cancer Research (University of Texas Health Science Center at San Antonio) Postdoctoral Fellow – Cancer Genomics (University of Texas Health Science Center at Houston) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Mammary Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|